Welcome to our FAQs on Brexit and your IP. Please click the questions in the list below to read the detailed responses. If you have any questions about Brexit and your IP portfolio that aren't covered below, or would like to speak to an IP adviser for detailed responses, don't hesitate to get in touch with our Brexit taskforce.
Cloning of EU rights
Use and reputation
- UK perspective:
- EU perspective:
If a corresponding UCD was established before 1 January 2021 through first disclosure in the EU but outside of the UK, this will not affect the validity of the continuing unregistered design.
- people resident in the UK or a qualifying country
- businesses formed under the laws of the UK or a qualifying country
Where qualification is a result of first marketing, you will need to have disclosed your design in the UK or a qualifying country.
It is not possible to have ‘dual disclosure’ of a design in both the UK and the EU, first disclosure can only be in the UK or EU. Protection will be given in the jurisdiction where first disclosure of the design occurs.
Supplementary Protection Certificates (SPCs)
- MAs which have been converted from existing EMA MAs: valid across the whole UK;
- MAs granted by the EMA: valid for NI;
- MAs granted by the MHRA: valid in England, Scotland and Wales only.
As companies increasingly turn to innovative trademarks, such as colour, sound, holograms and motion marks, to differentiate themselves from competitors, questions arise as to how to protect these trademarks effectively. Sign up to our webinar on 15 September to discover the answers.
In June 2022, the World Trade Organization approved the temporary lifting of patents for COVID-19 vaccines. Robert Balsters explains what this means in practice.
Businesses that are managing different brand names for the same products in different jurisdictions could save time and money by harmonising their trademark portfolio, says Luke Portnow.